Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to -$168.7 million.

  • Niagen Bioscience's Retained Earnings rose 1080.39% to -$168.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$168.7 million, marking a year-over-year increase of 1080.39%. This contributed to the annual value of -$181.9 million for FY2024, which is 448.91% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Retained Earnings is -$168.7 million, which was up 1080.39% from -$173.2 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Retained Earnings registered a high of -$154.8 million during Q2 2021, and its lowest value of -$191.0 million during Q2 2024.
  • For the 5-year period, Niagen Bioscience's Retained Earnings averaged around -$180.4 million, with its median value being -$183.6 million (2022).
  • Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 1912.78% in 2021, then skyrocketed by 1080.39% in 2025.
  • Over the past 5 years, Niagen Bioscience's Retained Earnings (Quarter) stood at -$169.0 million in 2021, then fell by 9.79% to -$185.5 million in 2022, then decreased by 2.68% to -$190.5 million in 2023, then grew by 4.49% to -$181.9 million in 2024, then grew by 7.28% to -$168.7 million in 2025.
  • Its Retained Earnings was -$168.7 million in Q3 2025, compared to -$173.2 million in Q2 2025 and -$176.8 million in Q1 2025.